Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
The management board of Evotec SE (Frankfurt Stock Exchange, TRQX:EVTd, ISIN: US30050E1055) resolved on 6 November 2025 to impl...
Evotec (NASDAQ:EVO) affirms FY2025 sales outlook from $861.690 million-$907.042 million to $861.690 million-$907.042 million.
Evotec (NASDAQ:EVO) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. This is a 16.67 pe...
Evotec SE (Frankfurt Stock Exchange:EVT, SDAX/TecDAX, Prime Standard, TRQX:EVTd(TRQX:EVTdFTRQX:EVTdrTRQX:EVTdaTRQX:EVTdnTRQX:EV...
Advances made in preclinical pipeline addressing neurodegenerative diseasesEvotec receives US$ 25 m payment to support continue...
HC Wainwright & Co. analyst Douglas Tsao maintains Evotec (NASDAQ:EVO) with a Buy and lowers the price target from $8 to...
Guidance for full-year 2025Group revenues expected in a range of € 760 - 800 m (2024: € 797.0 m)R&D expenditures are expect...
